NCT01002950 - Study of the Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of ACU-4429 in Subjects With Geographic Atrophy | Biotech Hunter

Enrollment

Participants

Timeline

Start Date

October 31, 2009

Primary Completion Date

June 30, 2012

Study Completion Date

October 31, 2012

Conditions

Dry Age-related Macular DegenerationGeographic Atrophy

Interventions

DRUG

ACU-4429

ACU-4429 tablets (2, 5, 7, or 10 mg) taken orally once daily for 90 days

DRUG

Matching placebo

Matching placebo tablets taken orally once daily for 90 days

Trial Locations (12)

New York Eye and Ear Infirmary, New York

Covance Clinical Research Unit, Inc., Daytona Beach

National Ophthalmic Research Institute, Fort Meyers

Cleveland Clinic, Cleveland

Associated Retinal Consultants, P.C. / William Beaumont Hospital, Royal Oak

Kresege Eye Institute, Detroit

Black Hills Regional Eye Institute, Rapid City

Covance Clinical Research Unit, Inc., Dallas

Covance Clinical Research Unit, Austin

Retinal Consultants of Arizona, Phoenix

Retina-Vitreous Associates Medical Group, Beverly Hills

Covance Clinical Research Unit, Inc., Honolulu